Clinical Trials on Pandemic Influenza in Germany

Total 131 results

GlaxoSmithKline

Completed

Safety Study of Pandemic Candidate Influenza Vaccines in the Elderly Population

Influenza | Influenza Vaccines

Germany
University Children's Hospital, Wuerzburg
GlaxoSmithKline; University of Wuerzburg

Unknown

Surveillance of Influenza in Paediatric Intensive Care Units in Bavaria

Influenza | Acute Respiratory Infection

Germany
Novartis Vaccines

Completed

Safety and Immunogenicity of a Cell Derived Subunit Trivalent Nonadjuvated Influenza Study Vaccine in Adults Aged 18 Years and Above

Influenza

Germany
Novartis Vaccines

Completed

Safety of a Influenza Vaccine Produced Either in Mammalian Cell Culture or in Embryonated Hen Eggs in Adults and Elderly With and Without Underlying Medical Conditions, and Immunogenicity in a Subset of Subjects With Underlying Medical Conditions

Seasonal Influenza | Vaccine

Germany
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity Study of the Influenza Vaccine in Adults

Influenza | Orthomyxoviridae Infections

Belgium, Germany, Switzerland
Sanofi Pasteur, a Sanofi Company

Completed

Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2022/23

Influenza (Healthy Volunteers)

Germany, Finland
Harding Center for Risk Literacy

Recruiting

Equity Evaluation of Fact Boxes on Informed COVID-19 and Influenza Vaccination Decisions - Study Protocol

COVID-19 | Influenza

Germany
Klinikum Bayreuth GmbH

Completed

Detection of Influenza or SARS-CoV-2 Infection by IMS of Nasal Air Sampling

Influenza

Germany
GlaxoSmithKline

Completed

Safety & Immunogenicity of an Alternative Immunization Schedule of GSK Bio's Pandemic Influenza Vaccine (GSK1119711A)

Influenza | Influenza Vaccines

Germany
Sanofi Pasteur, a Sanofi Company

Completed

Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2021/22

Influenza (Healthy Volunteers)

Germany, Finland
Ology Bioservices

Completed

Safety and Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived)

Influenza

Austria, Germany, Poland
GlaxoSmithKline

Completed

Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1)

Influenza

Germany
Charite University, Berlin, Germany

Terminated

Action of Caffeinated and Decaffeinated Espresso on Autonomic Function

Influence of Espresso on Heart Rate Variability

Germany
Sanofi Pasteur, a Sanofi Company

Completed

Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Europeans Adults 60 Years of Age and Older

Healthy Volunteers | Influenza Immunization

France, Belgium, Germany, Italy, Netherlands, Poland
GlaxoSmithKline

Terminated

Study to Evaluate the Immune Response and the Safety of Fluarix TM/ Influsplit SSW® 2010/2011 or Pandemrix TM

Influenza

Germany
Seqirus
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Immunosuppressive Conditions *aH5N1:Monovalent H5N1 Influenza Vaccine

Influenza | Influenza, Human | Influenza A Virus, H5N1 Subtype | Flu, Human | Flu, Avian

Australia, Germany, Italy
GlaxoSmithKline

Completed

Study to Evaluate the Safety and Immunogenicity of Pandemic Monovalent (H5N1) Influenza Vaccines (Whole Virus Formulation) in Adults 18 and 60 Years of Age

Influenza

Germany
GlaxoSmithKline

Completed

Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children

Influenza

Germany
GlaxoSmithKline

Completed

Study to Evaluate Immunological Equivalence Between Two Investigational Influenza Vaccines in Adults (H1N1)

Influenza

France, Germany
LMU Klinikum

Completed

Cardiovascular Prevention During COVID-19 Pandemic Lockdown in Young Adults (COLA Trial)

Cardiovascular Prevention Behaviour

Germany
GlaxoSmithKline

Completed

Immuno & Reacto of TF Trivalent Influenza Split Vaccine 2003/04 or of Std Formulation Influsplit SSW®/Fluarix™ 2003/04

Influenza

Germany
GlaxoSmithKline

Completed

Enhanced Safety Surveillance of GlaxoSmithKline's (GSK's) Quadrivalent Seasonal Influenza Vaccines During the 2018/19 Influenza Season

Influenza, Human

Germany, Spain, Belgium
Johannes Gutenberg University Mainz

Unknown

Evaluation of Transnasal Endoscopy During COVID-19 Pandemic

Endoscopy

Germany
GlaxoSmithKline

Completed

Study on the Immunogenicity and Tolerability of Influsplit SSW® 2005/2006 in Children Aged 6 - 13 Years

Influenza

Germany
University Hospital Heidelberg

Completed

Towards Better Preparedness for Future Catastrophes - Local Lessons-learned From COVID-19

Emergencies | COVID-19 Pandemic

Germany
Hoffmann-La Roche

Completed

Influenza Resistance Information Study (IRIS)

Influenza

Australia, Hong Kong, United States, France, Germany, Netherlands, Norway, Poland
University of Cologne

Completed

Effects of Contact Restrictions During the COVID-19 Pandemic on Newborns and Their Parents

Mother-Child Interaction

Germany
GlaxoSmithKline

Completed

Study to Evaluate an Influenza Vaccine Candidate

Influenza

France, Spain, Germany
Heinrich-Heine University, Duesseldorf

Recruiting

Immune Response to Seasonal Influenza Vaccination in Multiple Sclerosis Patients Receiving Cladribine (CIRMS)

Multiple Sclerosis, Relapsing-Remitting | Vaccine Response Impaired

Germany
Universitätsklinikum Hamburg-Eppendorf
King's College Hospital NHS Trust

Recruiting

Multicentre Study to Record the Mental and Physical Effects of the COVID-19 Pandemic (COBESITY-Study)

Overweight and Obesity | COVID-19 Pandemic

Germany
Hoffmann-La Roche

Completed

A Pharmacokinetic/Pharmacodynamic (PK/PD) and Safety Evaluation of Oseltamivir [Tamiflu] in the Treatment of Infants 0 to <12 Months of Age With Confirmed Flu Infection

Influenza

Belgium, Poland, France, Germany, Italy, Spain
GlaxoSmithKline

Completed

Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine in Elderly People

Influenza

Germany, Sweden, Netherlands
GlaxoSmithKline

Completed

Evaluation of Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Years and Older

Influenza

Germany, Sweden, Netherlands
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of JNJ-63623872 in Combination With Oseltamivir in Adult, and Elderly Hospitalized Participants With Influenza A Infection

Influenza A Virus

United States, France, Belgium, Germany, Hong Kong, Spain, Malaysia, Turkey, Canada, Netherlands, Singapore, Brazil, New Zealand, Australia, Sweden
Novartis Vaccines

Completed

Observational Study of Safety of Flu Cell Culture Derived Adjuvanted Swine Origin A (H1N1) Pandemic Subunit Vaccine

Novel Influenza A (H1N1) | A New Flu Virus of Swine Origin

Chile, Colombia, Germany, Switzerland
Seqirus

Completed

A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of Age

Influenza, Human

United States, Estonia, Germany
GlaxoSmithKline

Completed

Evaluate Safety & Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults

Influenza

Germany, United States, Belgium, Norway
GlaxoSmithKline

Completed

Immunogenicity and Safety Study to Evaluate Different Formulations of GSK Biologicals' Influenza Vaccine GSK576389A

Influenza

Germany, Sweden, United Kingdom, Netherlands
GlaxoSmithKline

Completed

Demonstrate the Superiority of the Immune Response of Adjuvanted Influenza Vaccine Induced in an Adult Population

Influenza

Germany, United States, Belgium, Norway
GlaxoSmithKline

Completed

Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged 18 Years and Above

Influenza

France, Spain, Germany, Russian Federation, Estonia, Sweden, Netherlands
University Hospital Tuebingen

Active, not recruiting

Immunity to Infection in Healthy Participants and Participants With Cancer (SYS01)

Solid Tumor | Influenza | SARS-CoV-2 | Hematologic Malignancy

Germany
Ology Bioservices

Completed

Phase 3 Study of a H5N1 Vaccine in Adults, Elderly and Specified Risk Groups

Influenza

Austria, Belgium, Finland, Germany, Latvia, Lithuania, Netherlands
University of Minnesota
National Institute of Allergy and Infectious Diseases (NIAID); National Institutes...

Completed

Respiratory Virus Outpatient Study (FLU 002 Plus)

Influenza and Other Novel Respiratory Viruses

United States, Chile, United Kingdom, Spain, Argentina, Australia, Thailand, Peru, Germany, Japan, Greece, Belgium, Denmark, Estonia, Poland
GlaxoSmithKline

Completed

Evaluation of the Safety and Immunogenicity of the Influenza Vaccine GSK2186877A in the Elderly

Influenza

Germany, United States, Belgium, Norway
ModernaTX, Inc.

Completed

A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older

Seasonal Influenza

Spain, United States, Denmark, Poland, United Kingdom, Germany, Canada, Taiwan, Bulgaria, Netherlands, Estonia
GlaxoSmithKline

Completed

Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hib Vaccines

Neisseria Meningitidis | Haemophilus Influenzae Type b

Spain, Germany, Poland
Charite University, Berlin, Germany

Completed

Effects of Integrative Medicine on Infectious Respiratory Diseases Including COVID-19 (AtemNHK)

Covid19 | Influenza A | Respiratory Disease

Germany
Janssen Research & Development, LLC
Janssen Pharmaceuticals

Completed

Study of Acute Uncomplicated Seasonal Influenza A in Adult Subjects

Influenza A

United States, Germany, Bulgaria, Canada, Estonia, Latvia, Belgium, Puerto Rico
Seqirus
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Underlying Medical Conditions

Influenza, Human

Germany
GlaxoSmithKline

Completed

Study on the Incidence of Influenza and Its Complications, in Subjects Aged 50 Years and Over Vaccinated With Fluarix™

Influenza

United States, Germany, Poland, Netherlands

3

Subscribe